Keyword Search
PRESS RELEASE
Sep 30, 2026
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
PRESS RELEASE
Sep 28, 2026
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
PRESS RELEASE
Sep 22, 2026
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs
PRESS RELEASE
Aug 14, 2026
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
PRESS RELEASE
Jul 23, 2026
Lantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern Time
PRESS RELEASE
Jun 26, 2026
Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)
PRESS RELEASE
Jun 03, 2026